| Patents for A61K 35 - Medicinal preparations containing material or reaction products thereof with undetermined constitution (125,838) |
|---|
| 01/23/2003 | US20030017587 Embryonic stem cells, clinical applications and methods for expanding in vitro |
| 01/23/2003 | US20030017510 Apparatus for use in cell transplantation |
| 01/23/2003 | US20030017478 Collection of prokaryotic DNA for two hybrid systems Helicobacter pylori protein-protein interactions and application thereof |
| 01/23/2003 | US20030017212 Fascilitates the proliferation of rat ascinar cells (ar42j) |
| 01/23/2003 | US20030017174 Containing herpes simplex virus VP22 polypeptides capable of eliciting a cellular immune response |
| 01/23/2003 | US20030017173 Arrestable therapeutic viral agent |
| 01/23/2003 | US20030017172 Feline polynucleotide vaccine formula |
| 01/23/2003 | US20030017157 Endothelial cell expression patterns |
| 01/23/2003 | US20030017153 Determining whether a patient's immune system can be modified through stimulation of thymus function; sex steroids are ablated in the patient, and the resulting production of thymic factors is monitored. |
| 01/23/2003 | US20030017152 Administering a substance that specifically depletes alpha beta -, and gamma delta -TCR+ T cells and/or CD8+ T cells, followed by transplantation with a donor cell preparation containing hematopoietic stem cells from a matched donor |
| 01/23/2003 | US20030017146 Particularly an arginine decarboxylase that is a biosynthetic enzyme of E. Coli; treatment of cancer |
| 01/23/2003 | US20030017143 Reduction of risk of rejection of allografts and xenografts and autoimmune diseases using the human suppressor CD8+CD28- T cells |
| 01/23/2003 | US20030017141 Treatment of conditions characterized by a need to modulate migratory-cell movement associated with specific sites in a subject; isolating a stromal-cell-derived fugetactic agent |
| 01/23/2003 | US20030017140 Retroviral vector particles have a chimeric envelope protein consisting of an antigen binding site of an antibody or another peptide, fused to the envelope protein the retroviral vector. |
| 01/23/2003 | CA2821544A1 Use of follistatin for the treatment of pulmonary fibrosis and fibrosis associated with inflammatory bowel disease |
| 01/23/2003 | CA2453928A1 Cell and transgenic animal modelling human antigenic presentation and their uses |
| 01/23/2003 | CA2453531A1 Methods for genetic modification of hematopoietic progenitor cells and uses of the modified cells |
| 01/23/2003 | CA2453470A1 Use of follistatin for the treatment of hepatic fibrogenesis |
| 01/23/2003 | CA2453438A1 Cells of the cardiomyocyte lineage produced from human pluripotent stem cells |
| 01/23/2003 | CA2453405A1 Pseudotyped adeno-associated viruses and uses thereof |
| 01/23/2003 | CA2453381A1 Methods for ex vivo propagation of somatic stem cells |
| 01/23/2003 | CA2453357A1 Anti-neoplastic viral agents |
| 01/23/2003 | CA2453187A1 Production of transduced hematopoietic progenitor cells |
| 01/23/2003 | CA2453183A1 In vivo production of small interfering rnas that mediate gene silencing |
| 01/23/2003 | CA2452517A1 Recombinant vsv for the treatment of tumor cells |
| 01/23/2003 | CA2451670A1 Enteral formulations |
| 01/23/2003 | CA2434303A1 Method for obtaining a tgf-beta enriched protein fraction in activated form, protein fraction and therapeutic applications |
| 01/22/2003 | EP1277464A2 Liposome coated with polyhydroxyalkanoate and production method thereof |
| 01/22/2003 | EP1276878A2 Reversible immortalization |
| 01/22/2003 | EP1276856A1 Albumin fusion proteins |
| 01/22/2003 | EP1276853A1 Pneumovirus ns proteins antagonising the interferon (ifn) response |
| 01/22/2003 | EP1276852A2 Viruses comprising mutated ion channel protein |
| 01/22/2003 | EP1276851A2 Tolerance-inducing thymus-bone marrow composite tissue construct and organ |
| 01/22/2003 | EP1276850A2 Human müllerian duct-derived epithelial cells and methods of isolation and uses thereof |
| 01/22/2003 | EP1276849A2 Albumin fusion proteins |
| 01/22/2003 | EP1276488A1 Use of lactic acid bacterium for the treatment of peritonitis |
| 01/22/2003 | EP1276487A1 Treatment of conditions of the central nervous system using mycobacteria |
| 01/22/2003 | EP1276486A2 Joint repair using mesenchymal stem cells |
| 01/22/2003 | EP1276457A1 A composition based on natural extracts useful in the prevention and treatment of cutaneous wrinkles |
| 01/22/2003 | EP1276431A1 Method for expansion of epithelial stem cells |
| 01/22/2003 | EP1276392A2 Nutritional modules |
| 01/22/2003 | EP1124633B1 Use of an adsorbent gel for eliminating and purifying biomolecules |
| 01/22/2003 | EP0853660B1 Method for preserving infectious recombinant viruses, aqueous viral suspension and use as medicine |
| 01/22/2003 | CN1391951A Burn paste and its preparing method |
| 01/22/2003 | CN1391934A Chinese medicine prepn for expelling toxin and resisting cancer and its preparing method and use |
| 01/22/2003 | CN1391931A Medicine for curing herpes zoster |
| 01/22/2003 | CN1391930A External medicine for curing gynaecological imflammation and its preparing method |
| 01/22/2003 | CN1391927A Medicine for curing rheumatism and rheumatoid arthritis |
| 01/22/2003 | CN1391917A Zhenggutongbi pill for curing bone disunion, aseptic bone necrosis and chronic osteomyelitis and its preparing method |
| 01/22/2003 | CN1391912A Kidney invigorating and bone strengthening medicine and its preparing method |
| 01/22/2003 | CN1391906A Novel lipase inhibitor |
| 01/22/2003 | CN1391905A Microbial preparation for curing intestinal diseases |
| 01/22/2003 | CN1391880A Electric moxibustion instrument |
| 01/22/2003 | CN1099289C Microbial preparation for improving intenstinal ecological balance and its process |
| 01/21/2003 | US6509147 Method for therapeutic immunmodulation of plasma |
| 01/21/2003 | US6509146 Scalable long-term shelf preservation of sensitive biological solutions and suspensions |
| 01/21/2003 | CA2235709C Absorbable dietary composition for improving the biological balance of intestinal tract flora |
| 01/21/2003 | CA2106952C A single dose vaccination system |
| 01/21/2003 | CA2098720C Cellular composition for the treatment of human or animal organisms |
| 01/21/2003 | CA1341417C Hirudine-expressing vectors, altered cells, and a process for hirudine preparation |
| 01/16/2003 | WO2003004661A2 Adenovital vectors with cell type specificity for mesenchymal cells |
| 01/16/2003 | WO2003004657A1 Polynucleotides encoding antigenic hiv type b and/or type c polypeptides, polypeptides and uses thereof |
| 01/16/2003 | WO2003004655A2 Use of the cd24 marker gene for the selection of keratinocyte stem cells transformed by exogenous sequences |
| 01/16/2003 | WO2003004651A1 Novel surface exposed immunoglobulin d-binding protein from moraxella catarrhalis |
| 01/16/2003 | WO2003004625A1 Methods of generating human cd4+ th2 cells and uses thereof |
| 01/16/2003 | WO2003004622A2 Human secreted proteins |
| 01/16/2003 | WO2003004620A2 Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
| 01/16/2003 | WO2003004520A2 Mycobacterial antigens expressed during latency |
| 01/16/2003 | WO2003004517A2 Peyers's patch and/or m-celle targeting ligands |
| 01/16/2003 | WO2003004066A1 Gene therapeutics |
| 01/16/2003 | WO2003004056A1 Method for treating multiple myeloma |
| 01/16/2003 | WO2003004039A2 Composition comprising soy and use thereof in the prevention and/or treatment of various diseases |
| 01/16/2003 | WO2003004037A1 Xenogenic oligoor/and polyribonucleotides as agents for the treatment of malignant tumours |
| 01/16/2003 | WO2003003855A1 Nutrition supplement or drug against specified deficiency conditions and cerebral dysfunctions |
| 01/16/2003 | WO2002045724A3 Use of modified mammalian blood for treating transforming growth factor related diseases |
| 01/16/2003 | WO2002044343A3 Tolerizing allografts of pluripotent stem cells |
| 01/16/2003 | WO2002042445A3 Differentiated cells suitable for human therapy |
| 01/16/2003 | WO2002040540A3 Artery smooth muscle- and vein smooth muscle-specific proteins and uses therefor |
| 01/16/2003 | WO2002038104A3 Compositions and methods for reducing the amount of salmonella in livestock |
| 01/16/2003 | WO2002022107A3 Pharmaceutical composition having modified carrier |
| 01/16/2003 | WO2002022080A8 Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol, nef and modifications |
| 01/16/2003 | WO2002020813A3 Recombinant endothelial cell growth inhibitors derived from a mammalian plasminogen |
| 01/16/2003 | WO2002018546A3 Plasma-derived-fibrin-based matrices and tissue |
| 01/16/2003 | WO2002007774A3 Methods for therapy of neurodegenerative disease of the brain |
| 01/16/2003 | WO2001092549A3 Method and composition for targeting an adenoviral vector |
| 01/16/2003 | US20030014770 Alpha (1,3) galactosyl transferase negative swine |
| 01/16/2003 | US20030013858 Fractionating crude extract with water soluble biologically active components; low and high molecular weight components are separated; anti -angiogenic, -tumor, -inflammatory and -collagenolytic |
| 01/16/2003 | US20030013669 Method of treating HIV infection and related secondary infections thereof |
| 01/16/2003 | US20030013668 Antiarthritic agents; inflammatory bowel disease; multiple sclerosis |
| 01/16/2003 | US20030013661 Method of producing fractions containing a high concentration of milk basic cystatin and decomposition products thereof |
| 01/16/2003 | US20030013193 Culturing preferential neurons; obtain neurons, incubate with mitogenic agent, graft cells, monitor differentiation in to neurons |
| 01/16/2003 | US20030013192 Method for neural stem cell differentiation using valproate |
| 01/16/2003 | US20030013191 Transgenic cells for use in human therapeutics and diagnostics |
| 01/16/2003 | US20030013190 Altered strain of the modified vaccinia virus ankara (mva) |
| 01/16/2003 | US20030012823 Submucosa gel compositions |
| 01/16/2003 | US20030012822 Forming a shape retaining gel by enzymatically hydrolyzing warm-blooded vertebrate submucosa; fractionating the hydrolysate; and gelling by adjusting the pH to 6.0-8.0; suitable for inducing cell proliferation and growth |
| 01/16/2003 | US20030012821 Continuous acidification demineralization process for producing osteoinductive bone; and osteoinductive bone produced thereby |
| 01/16/2003 | US20030012819 Method of preparing biological materials and preparations produced using same |
| 01/16/2003 | US20030012794 Kits comprising heat shock protein-antigenic molecule complexes |
| 01/16/2003 | US20030012791 Use of cytokines and mitogens to inhibit graft versus host disease |